Working… Menu
Trial record 24 of 48 for:    ( Map: Gabon )

Efficacy, Safety and Pharmacokinetic of ArtequinTM P. Falciparum Malaria

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00243737
Recruitment Status : Completed
First Posted : October 25, 2005
Last Update Posted : January 24, 2013
Mepha Ltd.
Information provided by:
Albert Schweitzer Hospital

Brief Summary:
Treatment of Plasmodium falciparum malaria in Africa is increasingly difficult. Resistance to cheap efficient antimalarial drugs poses an increasing threat. The rapid emergence of resistance to sulfadoxine - pyrimethamine, already seen in East Africa is growing and is likely to have an striking impact on mortality in many other African regions where no obvious alternatives are available. WHO recommends the use of drug combinations containing artemisinin compounds, i.e., artemisinin-based combination therapies (ACT). Previous clinical trials have shown that the combination of artesunate with mefloquine is highly effective and well tolerated in the treatment of multidrug-resistant falciparum malaria, retaining the benefit of rapidity of action while augmenting cure rates, and apparently slowing the development of mefloquine resistance. Compliance with sequential combination regimen of antimalarial drugs is notoriously poor. Therefore, in order to limit the development of resistance to both drugs and ameliorate patients' compliance to antimalarial treatments, an optimal simultaneous combination regimen of artesunate and mefloquine in a practical single blister pack has been developed by Mepha Ltd. and successfully tested. The currently available

Condition or disease Intervention/treatment Phase
Malaria Drug: Artesunate-Mefloquine Phase 2

Detailed Description:
Artequin dosages could only be tested in children able to swallow tablets and with a body weight of more than 20 kg. However, there is a great need for an Artequin formulation for smaller children unable to swallow tablets. The new Artequin Paediatric oral formulation is a flavoured, taste-masked preparation of granules of 50 mg artesunate and 125 mg mefloquine as a fixed-dose combination (once daily in one single Stickpack, i.e. 3 Stickpacks for a 3-day treatment). It is suitable for children with up to 20 kg body weight (with a range of 10-20 kg).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 70 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open-label, Stratified Study on the Efficacy, Safety and Pharmacokinetic Characteristics of Two Paediatric Formulations of ArtequinTM in Children With Acute Uncomplicated P. Falciparum Malaria
Study Start Date : October 2005
Study Completion Date : April 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Malaria

Primary Outcome Measures :
  1. Efficacy, Proportion of patients cured on day 28

Secondary Outcome Measures :
  1. Efficacy: day 14v cure rate, parasite and fever clearance time, parasite reduction rate, gametocytemia, in relation to blood concentrations of Dihydroartemisinin and mefloquine, safety, tolerability, acceptability
  2. parasite and fever clearance time, parasite reduction rate, gametocytemia, in relation to blood concentrations of Dihydroartemisinin
    Time to complete clearance of fever and parasitemia Assessment in relation to DHA and mefloquine blood levels

  3. safety, tolerability, acceptability
    Assessment of adverse events and reporting of tolerability, safety and acceptability

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Male or female with a body weight ≥10 to 40 kg

  • Patients suffering from acute uncomplicated Plasmodium falciparum malaria
  • Malaria diagnosis confirmed by a positive blood smear with asexual forms of Plasmodium falciparum (i.e., identification of asexual parasite count ≥1,000 to 250,000 per mm3)
  • Ear temperature 37.5°C or a history of fever within the last 48 hours
  • Haemoglobin 7g/100ml
  • Written informed consent and written consent from parents/guardian for children below age of consent (verbal consent in presence of literate witness is required for illiterate patients or parents/guardians).

Exclusion Criteria:

Patients with signs and symptoms of severe/complicated malaria requiring parenteral treatment (defined according to WHO Recommendations "Malaria Control Today", RBM Working Document, March 2005, see Appendix 2)

  • Patients with known hypersensitivity or allergy to artemisinin derivatives or mefloquine or mefloquine chemically related compounds (for example quinine and quinidine)
  • Patients who had received quinine or any artemisinin derivatives within 12 hours prior to study start
  • Patients who had received any other adequate antimalarial drug therapy including antibiotics which might be active against malaria infection within 1 week prior to study start
  • Patients who had received investigational (unlicensed) drugs as well as mefloquine within 30 days prior to study start
  • Patients with known history of psychiatric disorders
  • Patients with known history of cardiac diseases and arrhythmia
  • Patients with known sickle cell disease
  • Patients with clinical signs of or laboratory evidence for any other severe hepatic, renal, pulmonary, cardiac, metabolic, psychiatric, cancer or haematologic diseases
  • Pregnancy or lactation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00243737

Layout table for location information
Medical Research Unit, Albert Schweitzer Hospital
Lambarene, Gabon
Département de Parasitologie-Mycologie, Faculte de medecine
Libreville, Gabon
Sponsors and Collaborators
Albert Schweitzer Hospital
Mepha Ltd.
Layout table for investigator information
Principal Investigator: Maryvonne Kombila, Prof Dr Département de Parasitologie-Mycologie, Faculté de médecine

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information Identifier: NCT00243737     History of Changes
Other Study ID Numbers: AM-P 001-2005
First Posted: October 25, 2005    Key Record Dates
Last Update Posted: January 24, 2013
Last Verified: January 2013
Keywords provided by Albert Schweitzer Hospital:
Additional relevant MeSH terms:
Layout table for MeSH terms
Malaria, Falciparum
Protozoan Infections
Parasitic Diseases
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents
Antineoplastic Agents
Antiviral Agents
Antiplatyhelmintic Agents